NCT06389110招募中3 期
Phase III Clinical Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay the Progression of Myopia and Axial Ocular Elongation in Children.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Changes in the spherical equivalent
研究概览
简要总结
Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children.
详细描述
This is a study to demonstrate superiority, double-blind, randomized, controlled, comparative, and multicenter phase III clinical trial.
Primary Objective:
- To demonstrate the superiority of Alleance® compared to placebo in delaying myopia progression in children.
Specific objectives:
- To demonstrate the reduction in progression in spherical equivalent in children using Alleance® compared to placebo after 12 months of treatment.
- To demonstrate the reduction in progression in ocular axial length in children using Alleance® compared to placebo, after 12 months of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 3 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Children aged between 3 to 12 years
- •Male or female sex.
- •The parent(s) or legal guardian(s) must voluntarily give their signed informed consent.
- •From the age of 7 years and older, the subject's willingness to participate in the research study will be expressed in writing. In the case of subjects under 7 years of age, only the signature of the informed consent by the parent(s) or legal guardian(s) will be required, provided that the subject's verbally expressed will is respected.
- •Ability and willingness to comply with the scheduled visits, treatment plan and other study procedures.
- •Female subjects, who have already presented their menarche, must have a negative urine pregnancy test at the time of screening.
- •Female subjects who have already experienced menarche should secure a method of contraception for the duration of the study. Acceptable contraceptive methods include abstinence (defined as abstinence from heterosexual intercourse from study entry until completion) or use of a highly effective contraceptive method, including hormonal contraception, barrier methods or intrauterine device).
- •Refractive error of spherical equivalent between -0.50 to -6.00 D in each eye, measured by autorefraction and cycloplegic retinoscopy.
- •Astigmatism less than -1.50 D in each eye, measured by autorefraction and retinoscopy.
- •Spherical equivalent anisometropia ≤ 1.50 D measured by autorefraction and cycloplegic retinoscopy.
- •Best corrected visual acuity (BCVA) normal for age.
- •Normal binocular function and stereopsis for age.
- •Normal intraocular pressure (< 21 mmHg).
- •Gestational age ≥ 32 weeks and birth weight > 1500 g.
排除标准
- •Allergy to atropine or any of the components of the investigational products.
- •Previous or current use of atropine, orthokeratology lens or other optical methods for myopia control (bifocal, progressive, multifocal, or defocusing air or contact lenses). Only prior or current use of frame lenses or monofocal contact lenses for the correction of myopic or myopic/astigmatic refractive error will be allowed.
- •History or current history of amblyopia or manifest strabismus, including intermittent tropia.
- •Heart rate > 120 beats per minute persistently (for more than 10 minutes) at the time of screening/baseline visit.
- •History of any disease or syndrome predisposing the subject to severe myopia (Marfan syndrome, Stickler syndrome, retinopathy of prematurity, etc.).
- •History of serious systemic disease that, in the investigator's judgment, would make the subject ineligible (e.g., cardiac, endocrine, respiratory, neurologic [infantile cerebral palsy], Down syndrome, etc.).
- •History or current history of glaucoma or ocular hypertension.
- •History of any refractive ocular anatomical anomaly (keratoconus, lenticonus, spherophakia, aphakia, etc.).
- •History of ocular diseases, excluding myopia (corneal alterations/opacities, cataract, retinal alterations, inflammatory diseases, etc.).
- •History of any type of ocular surgery.
- •For female subjects who have presented their menarche: being pregnant or breastfeeding.
- •Having participated in clinical research studies 30 days prior to inclusion in the present study.
- •Previous participation in this study.
- •Present unresolved ocular lesions or trauma at the time of study entry.
- •Present active inflammatory or infectious ocular disease at the time of study entry.
- •Having undergone surgical procedures, not ophthalmologic, within the last 3 months.
- •Chronic use of any topical or systemic antimuscarinic/anticholinergic medication (atropine, scopolamine, tropicamide) within 21 days prior to screening, and/or anticipated need for its chronic use during the study period (more than 7 consecutive days in a month or more than 30 days total in a year). The use of cycloplegic drops for ophthalmologic examination is allowed.
- •Be or have an immediate family member (e.g., parent/legal guardian or sibling) who is part of the research site or sponsor´s staff.
- •Elimination Criteria:
- •Withdrawal of their consent to participate in the study (informed consent form).
- •Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
- •Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).
- •Non-tolerability or hypersensitivity to any of the drugs under investigation.
- •Adherence < 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.
研究组 & 干预措施
Alleance®
Active Comparator
Alleance®. Atropine sulfate 0.01%. Ophthalmic solution.
- Dosage: 1 drop QD [1] (once a day), at night, for 12 months.
- Route of administration: Ophthalmic
干预措施: Alleance® (Drug)
Placebo
Placebo Comparator
- Placebo. Ophthalmic solution.
- Dosage: 1 drop QD [1] (once a day), at night, for 12 months.
- Route of administration: Ophthalmic
干预措施: Placebo (Drug)
结局指标
主要结局
Changes in the spherical equivalent
时间窗: Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call)
The reduction in progression in spherical equivalent, will be calculated by combining the spherical component (E) and the cylindrical component (C) of the refractive error, independently for each eye: EE=E+C2
Changes in axial eye length
时间窗: Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call)
The reduction in progression in ocular axial length will be measured utilizing optical biometry.
次要结局
- Incidence of unexpected adverse events related to the interventions(Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call))
- Changes in near best-corrected visual acuity(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
- Changes in the amplitude of accommodation (AA) between interventions(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
- Incidence of photophobia between interventions(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
- Changes in pupillary diameter between the interventions(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
- Changes in Best Corrected Visual Acuity (BCVA)(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
- Changes in intraocular pressure (IOP)(Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaDiabetic Macular EdemaNCT05217680Laboratorios Sophia S.A de C.V.509
尚未招募
不适用
Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and AdolescentsMyopia, ProgressiveNCT05597163Shanghai Eye Disease Prevention and Treatment Center588
终止
3 期
Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.Conjunctivitis, BacterialNCT03696342Laboratorios Sophia S.A de C.V.46
招募中
3 期
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia ProgressionMyopia ProgressionMyopiaNCT06708156Oupushifang Pharmaceutical Technology Co., Ltd.606
招募中
3 期
A Study in Chinese Patients With Acquired BlepharoptosisBlepharoptosisNCT06683651Santen Pharmaceutical Co., Ltd.180